Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1035235-27-8 | MDL No. : | MFCD10700130 |
Formula : | C13H16BrNO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BFCZVUVSPUKWET-UHFFFAOYSA-N |
M.W : | 298.18 | Pubchem ID : | 49853504 |
Synonyms : |
|
Num. heavy atoms : | 17 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.46 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 74.52 |
TPSA : | 29.54 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | Yes |
CYP2C9 inhibitor : | Yes |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.08 cm/s |
Log Po/w (iLOGP) : | 3.25 |
Log Po/w (XLOGP3) : | 2.87 |
Log Po/w (WLOGP) : | 3.02 |
Log Po/w (MLOGP) : | 2.92 |
Log Po/w (SILICOS-IT) : | 2.85 |
Consensus Log Po/w : | 2.98 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.56 |
Solubility : | 0.0821 mg/ml ; 0.000275 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.15 |
Solubility : | 0.211 mg/ml ; 0.000708 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.03 |
Solubility : | 0.0281 mg/ml ; 0.0000942 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 2.31 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
75% | With triethylamine In tetrahydrofuran at 10 - 20℃; for 12 h; | Step e. TEA (126 ml, 903 mmol) was added drop-wise over 5 min to a stirred suspension of 4- bromoisoindoline HQ (100 g, 430 mmol) in THF (700 ml) and the mixture was cooled to 10°C. The cooled mixture was then treated with a solution of di-tert-butyl dicarbonate (122 g, 559 mmol) in THF (300 ml) over 15 min whilst maintaining the temperature below 20°C, and the resulting mixture was stirred at rt for 12 h. The reaction was concentrated under vacuum to give an oil, which was partitioned between EtOAc (600 ml) and water (600 ml). The aqueous phase was collected and extracted with EtOAc (2 χ 500 ml), and the combined organic extracts were washed with brine, dried over Na2S04, filtered and evaporated to dryness under vacuum to give the crude product as a solid (161 g). The crude solid was slurried in hexane (150 ml), filtered and the resulting solid washed with hexane (60 ml) before being dried under vacuum at rt to give the desired product as a solid (95.7 g, 75percent). LCMS (Method R): rt 3.02 min, m/z 242 (-tBu)/198(-Boc) [M+H]+; NMR (400 MHz, DMSO-d6) δ ppm 7.51-7.46 (dd, J = 7.8, 0.6 Hz, 1H), 7.38-730 (m, 1H), 7.29-7.21 (m, 1H), 4.73- 4.63 (d, 2H), 4.56-4.47 (d, 2H), 1.50-1.42 (d, 9H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91% | With triethylamine In N,N-dimethyl-formamide at 20℃; for 18 h; | A solution of 4-bromoisoindoline hydrochloride (1.40 g, 5.97 mmol) in DMF (30 mL) was treated with triethylamine (2.50 mL, 17.9 mmol) and di-tert-butyl dicarbonate (2.08 mL, 8.95 mmol), and the mixture was stirred at room temperature for 18 h. Themixture was diluted with EtOAc (65 mL) and washed three times with saturated aqueousNaHCO3. The organic phase was dried and concentrated. The residue was subjected tocolumn chromatography on silica gel, eluting with EtOAc-hexanes (gradient from 0-3 0percent), to provide tert-butyl 4-bromoisoindoline-2-carboxylate as a white solid (1.70 g,91percent yield). |
[ 201940-08-1 ]
tert-Butyl 5-bromoisoindoline-2-carboxylate
Similarity: 0.94
[ 893566-75-1 ]
Tert-butyl 8-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate
Similarity: 0.93
[ 893566-74-0 ]
tert-Butyl 6-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate
Similarity: 0.88
[ 258515-65-0 ]
tert-Butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate
Similarity: 0.88
[ 68819-84-1 ]
tert-Butyl 4-bromobenzylcarbamate
Similarity: 0.87
[ 201940-08-1 ]
tert-Butyl 5-bromoisoindoline-2-carboxylate
Similarity: 0.94
[ 893566-75-1 ]
Tert-butyl 8-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate
Similarity: 0.93
[ 893566-74-0 ]
tert-Butyl 6-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate
Similarity: 0.88
[ 258515-65-0 ]
tert-Butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate
Similarity: 0.88
[ 68819-84-1 ]
tert-Butyl 4-bromobenzylcarbamate
Similarity: 0.87
[ 201940-08-1 ]
tert-Butyl 5-bromoisoindoline-2-carboxylate
Similarity: 0.94
[ 261732-38-1 ]
tert-Butyl 5-bromoindoline-1-carboxylate
Similarity: 0.77
[ 885272-46-8 ]
tert-Butyl 4-bromoindoline-1-carboxylate
Similarity: 0.76
[ 264916-06-5 ]
tert-Butyl 5-aminoisoindoline-2-carboxylate
Similarity: 0.73
[ 143262-17-3 ]
tert-Butyl 7-bromoindoline-1-carboxylate
Similarity: 0.72